16.23
-0.46(-2.76%)
Currency In USD
| Previous Close | 16.69 |
| Open | 16.49 |
| Day High | 16.71 |
| Day Low | 16.06 |
| 52-Week High | 29.3 |
| 52-Week Low | 14.72 |
| Volume | 748,955 |
| Average Volume | 806,392 |
| Market Cap | 1.48B |
| PE | -12.68 |
| EPS | -1.28 |
| Moving Average 50 Days | 21.06 |
| Moving Average 200 Days | 23.26 |
| Change | -0.46 |
If you invested $1000 in Myriad Genetics, Inc. (MYGN) 10 years ago, it would be worth $467.99 as of December 04, 2024 at a share price of $16.23. Whereas If you bought $1000 worth of Myriad Genetics, Inc. (MYGN) shares 5 years ago, it would be worth $628.34 as of December 04, 2024 at a share price of $16.23.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
GlobeNewswire Inc.
Nov 20, 2024 9:30 PM GMT
Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor typesSALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in gen
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
GlobeNewswire Inc.
Nov 19, 2024 1:00 PM GMT
SALT LAKE CITY, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that the Prequel® Prenatal Screen is now available at eight weeks into pregnancy. Enabled by its A
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
GlobeNewswire Inc.
Nov 13, 2024 1:00 PM GMT
SneakPeek®, the first at-home early fetal sex test for use at six weeks, is now available at over 8,800 retail locations nationwideSALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing